Apellis price target raised to $67 from $60 at Wedbush

Wedbush raised the firm’s price target on Apellis to $67 from $60 and keeps a Neutral rating on the shares. The firm says that with Apellis already providing a January preannouncement of key Q4 figures, the financial results report was largely as anticipated. Management noted they’ve observed typical seasonal headwinds for Syfovre in January/February. However, these months still demonstrated strong uptake. Wedbush continues to be on the sidelines as it awaits further clarity on the potential EU regulatory path for Syfovre.